adenosine-5--(n-ethylcarboxamide) and Lupus-Erythematosus--Systemic

adenosine-5--(n-ethylcarboxamide) has been researched along with Lupus-Erythematosus--Systemic* in 1 studies

Other Studies

1 other study(ies) available for adenosine-5--(n-ethylcarboxamide) and Lupus-Erythematosus--Systemic

ArticleYear
Characterization of the human T lymphocyte adenosine receptor: comparison of normal and systemic lupus erythematosus cells.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 1988, Mar-01, Volume: 2, Issue:3

    To determine whether a defect in the T cell response to adenosine exists at the level of the adenosine receptor in systemic lupus erythematosus (SLE) we measured the binding affinity and maximum binding of T cell membranes from both normal and SLE T cells by utilizing radiolabeled adenosine ligands. Normal T lymphocyte membranes possess a single class of [3H]5-N-ethylcarboxamide adenosine binding sites with a Kd of 0.61 microM, a Bmax of 23.5 pmol/mg protein, and a Hill coefficient of 0.98, which indicates the presence of noncooperative sites. In contrast, T cell membranes do not bind significant amounts of either [3H]cyclohexyladenosine or [3H]phenylisopropyladenosine. These data indicate that T lymphocyte membranes have only A2, and not A1, adenosine receptors. Similarly, T cells from both active and inactive SLE subjects also express only A2 receptors with a Kd of 0.93 microM, a Bmax of 20.4 pmol/mg protein, and a Hill coefficient of 0.85, which is consistent with the presence of noncooperative sites. There is no difference in the on-rate, affinity, or density of T cell A2 receptors from active SLE patients, inactive SLE patients, or healthy controls. We conclude that T lymphocytes from both healthy and SLE subjects express A2, but not A1, receptors. Thus, the inability of SLE T cells to respond to adenosine does not reflect a decreased density of A2 (stimulatory) receptors, diminished A2 receptor binding, or an increased affinity or number of A1 (inhibitory) adenosine receptors. These observations support the conclusion that the defect in the T cell cAMP-dependent pathway may occur at a point distal to the adenosine receptor.

    Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Binding Sites; Binding, Competitive; Cell Membrane; Female; Humans; Lupus Erythematosus, Systemic; Receptors, Purinergic; Reference Values; T-Lymphocytes

1988
chemdatabank.com